Evidence map›Paper›PMID 30323900›Full record

ArticleOncotarget2018

MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.

Michael J G Milevskiy, Gurveen K Sandhu, Anna Wronski, Darren Korbie, Brooke L Brewster, Annette Shewan, Stacey L Edwards, Juliet D French, Melissa A Brown

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. The Oncogenic Activity ofJournal of clinical medicine · 2019
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Michael J G MilevskiySchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Gurveen K SandhuSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Anna WronskiSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Darren KorbieAustralian Institute of Biotechnology and Nanotechnology, University of Queensland, St Lucia, Queensland, Australia.
Brooke L BrewsterSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Annette ShewanSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Stacey L EdwardsSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Juliet D FrenchSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
Melissa A BrownSchool of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Queensland, Australia.
University of Queensland · AUMolecular Oncology (United States) · USQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the protein-coding genes altered in BRCA1 deficient cells. However, the role of non-coding RNAs in BRCA1-deficient cells is poorly understood. To evaluate miRNA expression in BRCA1 deficient mammary cells, RNA sequencing was performed on the mammary glands of Brca1 knockout mice. We identified 140 differentially expressed miRNAs, 9 of which were also differentially expressed in human BRCA1 breast tumours or familial non-BRCA1 patients and during normal gland development. We show that BRCA1 binds to putative cis-elements in promoter regions of the miRNAs with the potential to regulate their expression, and that four miRNAs (miR-29b-1-5p, miR-664, miR-16-2 and miR-744) significantly stratified the overall survival of basal-like tumours. Importantly the prognostic value of miR-29b-1-5p was higher in significance than several commonly used clinical biomarkers. These results emphasise the role of Brca1 in modulating expression of miRNAs and highlights the potential for BRCA1 regulated miRNAs to be informative biomarkers associated with BRCA1 loss and survival in breast cancer.

Indexed as

biomarkerBRCA1breast cancermiRNA

Identifiers

PMID30323900
PMCPMC6173367
OpenAlexW2951285743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.